Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Hoarau

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
La Revue De Medecine Interne|July 8, 2017
A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID)J-F Viallard, J-P Brion, M Malphettes, et al.
Orphanet Journal of Rare Diseases|June 24, 2016
Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages"B Bienvenu, G Cozon, C Hoarau, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|March 23, 2011
Comparison between major histocompatibility complex class II tetramer staining and surface expression of activation markers for the detection of allergen-specific CD4⁺ T cellsM Bonvalet, E Wambre, H Moussu, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|November 26, 2010
Distinct characteristics of seasonal (Bet v 1) vs. perennial (Der p 1/Der p 2) allergen-specific CD4(+) T cell responsesE Wambre, M Bonvalet, V B Bodo, et al.
BMC Immunology|October 1, 2016
Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trialJ F Viallard, P Agape, V Barlogis, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
La Revue De Medecine Interne|July 8, 2017
A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID)J-F Viallard, J-P Brion, M Malphettes, et al.
Orphanet Journal of Rare Diseases|June 24, 2016
Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages"B Bienvenu, G Cozon, C Hoarau, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|March 23, 2011
Comparison between major histocompatibility complex class II tetramer staining and surface expression of activation markers for the detection of allergen-specific CD4⁺ T cellsM Bonvalet, E Wambre, H Moussu, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|November 26, 2010
Distinct characteristics of seasonal (Bet v 1) vs. perennial (Der p 1/Der p 2) allergen-specific CD4(+) T cell responsesE Wambre, M Bonvalet, V B Bodo, et al.
BMC Immunology|October 1, 2016
Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trialJ F Viallard, P Agape, V Barlogis, et al.
Pageof 2